Contrast medium indicated nephropathy

Česká verzia

Authors: D. Krusová; K. Ševela
Authors place of work: II. interní klinika Lékařské fakulty MU a FN u sv. Anny, Brno, přednosta doc. MUDr. Miroslav Souček, CSc.
Published in the journal: Vnitř Lék 2006; 52(9): 805-811
Category: Review

Summary

Contrast medium indicated nephropathy (CMIN) is a iatrogenic disorder by which patients become inflicted due to contrast medium exposure. Prevalence of this disorder might increase as more and more diagnostic and intervence radiology has been used. The article is focused on known pathofysiological mechanisms that are responsible for CMIN incidence. There are many risk factors guided by more frequent development of this complication, in particular diabetes mellitus, preexisting renal disease, hypertensis. Plus, the risk of CMIN is much higher in patients with risky medication. Measures to prevent contrast nephropathy coincidence are mentioned; however, some of them require more support and evidence in studies. The possible incidence of CMIN has to be taken into account and prevented by respective measures.

Key words:
nephropathy – contrast medium indicated nephropathy – risk factors – preventive measures

Zdroje

1. Merten GJ, Burgess WP, Gray LV et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: A randomized controlled trial. JAMA 2004; 291: 2328-2334.

2. Kandzari DE, Rebeiz AG, Wang A et al. Contrast nephropathy: an evidence-based approach to prevention. Am J Cardiovasc Drugs 2003; 3: 395-405.

3. Gami AS, Garovic VD. Contrast nephropathy after coronary angiography. Mayo Clin Proc 2004; 79: 211-219.

4. Rihal CS, Textor SC, Grill DE et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105: 2259-2264.

5. Cavusoglu E, Chhabra S, Marmur JD et al. The prevention of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention. Minerva Cardioangiol 2004; 52: 419-432.

6. Brendan J, Barrett MB, Parfey PS. Preventing Nephropathy Induced by Contrast Medium. N Engl J Med 2006; 354: 379-386.

7. Soma VR, Cavusoglu E, Vidhun R et al. Contrast-associated nephropathy. Heart Dis 2002; 4: 372-379.

8. Oudemans-van Straaten HM Contrast nephropathy, pathophysiology and prevention. Int J Artif Organs 2004; 27: 1054-1065.

9. Johnson RJ, Feehally J (eds). Comprehensive Clinical Nephrology. London: Harcourt 2003: 13-26, 215-216.

10. Katholi RE, Woods WT jr, Taylor GJ et al. Oxygen free radicals and contrast nephropathy. Am J Kidney Dis 1998; 32: 64-71.

11. Idée JM, Lancelot E, Pines E et al. Prophylaxis of iodinated contrast media-induced nephropathy: a pharmacological point of view. Invest Radiol 2004; 39: 155-170.

12. Štípek S et al. Antioxidanty a volné radikály ve zdraví a nemoci. 1. ed. Praha: Grada Publishing 2000, 77-92.

13. Welch WJ, Tojo AB, Wilcox CS Roles of NO and oxygen radicals in tubuloglomerular feedback in SHR. Am J Physiol Renal Physiol 2000; 278(5): F769-F776.

14. Liang M, Knox FG. Production and functional roles of nitric oxide in the proximal tubule. Am J Physiol 2000; 278: 47.

15. Goldenberg I, Matetzky S. Nephropathy induced by contrast media: Pathogenesis, risk factors and preventive strategies. Can Med Assoc J 2005; 172: 1461-1471.

16. Schuck O, Tesař V, Teplan V. Klinická nefrologie. 1.ed. Praha: Medprint 1995: 266.

17. Zager RA, Johnson,AC, Hanson SY. Radiographic contrast media-induced tubular injury: Evaluation of oxidant stress and plasma membrane integrity. Kid Int 2003; 64: 128-139.

18. Harwood SM, Yaqoob MM, Allen DA Caspase and calpain function in cell death: Bridging the gap between apoptosis and necrosis. Ann Clin Biochem 2005; 42: 415-431.

19. Chertow GM. Prevention of radiocontrast nephropathy: Back to basics. J Am Med Assoc 2004; 291: 2376-2377.

20. Aspelin P, Aubry P, Fransson SG et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003; 348: 491-499.

21. Spinazzi A, Pozzi Mucelli R. Administration of iodinated contrast in patients with pre-existing renal failure. Radiol Med (Torino) 2004; 107: 88-97.

22. Briguiori C, Tavano D, Colombo A. Contrast agent-associated nephrotoxicity. Prog Cardiovasc Dis 2003; 45: 493-503.

23. Haglund M, Hesselstrand R, Nyman U et al. Contrast-induced nephropathy after computer tomography. Hydration and adapted contrast media dosage for the best prophylaxis. Lakartidningen 2005; 102: 2864-2866, 2869-2870.

24. Bader. BD, Berger ED, Heede MB et al. What is the best hydration regimen to prevent contrast media-induced nephrotoxicity? Clinical Nephrology 2004; 62: 1-7.

25. The Royal Australian and New Zealand College of Radiologists: Guidelines for Metformin Hydrochloride and Intravascular Contrast, 2006; http://www.ranzcr.edu.au/collegegroups/reference/EBM/mhicm_guidelines.cfm

26. McCullough PA, Soman SS. Contrast-induced nephropathy. Crit Care Clin 2005; 21: 261-280.

27. Stříbrná J, Peregrin JH, Teplan V. Radiocontrast induced nephropathy. Prakt Lék 2003; 83: 270-272.

28. Bridges JM, Feldstein DA. Preventing contrast-induced nephropathy: a basic solution. WMJ 2005; 104: 9-10.

29. Asher I, Hammerman A, Sthoeger Z. New usage for an old drug: acetylcysteine for contrast-induced nephropathy. Harefuah 2005; 144: 642-646; 675.

30. Guru V, Fremes SE. The role of N-acetylcysteine in preventing radiographic contrast-induced nephropathy. Clin Nephrol 2004; 62: 77-83.

31. Birck R, Krzossok S, Markowetz F. Acetylcysteine for prevention of contrast nephropathy: Meta-analysis. Lancet 2003; 362: 598-603.

32. Shjalansky SJ, Vu T, Pate GE et al. N-acetylcysteine for prevention of radiographic contrast material-induced nephropathy: is the intravenous route best? Pharmacotherapy 2005; 25: 1095-1103.

33. Vallero A, Cesano G, Pozzato M. Contrast nephropathy in cardiac procedures: No advantages with prophylactic use of N-acetylcysteine. G Ital Nefrol 2002; 19: 529-533.

34. Gomea VO, Poli De Figueredo, Caramori P. N-acetylcysteine does not prevent contrast induced nephropathy with an ionic low osmolality contrast medium: A multicentre clinical trial. Heart 2005; 91: 774-778.

35. Murphy SW, Barrett BJ, Parfrey PS. Contrast nephropathy. J Am Soc Nephrol 2000; 11: 177-182.